The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Press briefing: primary results from the Phase III EPCORE FL-1 trial
In this press briefing, Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares primary results from the Phase III Epcore FL-1 trial (NCT05409066) evaluating epcoritamab with rituximab and lenalidomide (R2) versus R2 for patients with relapsed/refractory (R/R) follicular lymphoma. This press briefing took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
